Solid Biosciences (SLDB) investor relations material

Executive summary

• Advanced gene therapy candidates for rare neuromuscular and cardiac diseases, including SGT-003 (Duchenne), SGT-212 (Friedreich's ataxia), SGT-501 (CPVT), and SGT-601 (TNNT2 DCM).

• SGT-003 dosed first participant in Phase 3 IMPACT DUCHENNE trial and 47 participants in Phase 1/2 INSPIRE DUCHENNE trial, showing encouraging safety and tolerability.

• SGT-212 dosed two participants in Phase 1b FALCON trial with no serious adverse events; SGT-501 expected to begin dosing in H2 2026.

• SGT-003 and SGT-212 received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA; SGT-003 also received EU Orphan Drug and UK Innovation Passport status.

• Net loss increased to $56.7 million for Q1 2026, with an accumulated deficit of $1.0 billion as of March 31, 2026.

Financial highlights

• Cash, cash equivalents, and available-for-sale securities totaled $380.7 million as of March 31, 2026, up from $187.9 million at December 31, 2025.

• Research and development expenses rose 49.3% year-over-year to $46.1 million, mainly due to increased SGT-003 and SGT-212 costs.

• General and administrative expenses increased 22.2% year-over-year to $11.2 million, driven by higher personnel and consulting costs.

• Net loss per share was $0.52, compared to $0.59 in Q1 2025.

• Financing activities provided $239.0 million in Q1 2026, primarily from a $226.3 million private placement.

Outlook and guidance

• Cash runway expected to fund operations into the first half of 2028, but future capital needs are anticipated.

• Ongoing and planned clinical trials for SGT-003, SGT-212, and SGT-501, with initial data from SGT-212 expected by end of 2026 and SGT-501 in 2027.

• Ongoing engagement with FDA for potential accelerated approval pathway for SGT-003.

• Continued focus on expanding pipeline and advancing clinical and preclinical programs.